Development of Zeise's Salt Derivatives Bearing Substituted Acetylsalicylic Acid Substructures as Cytotoxic COX Inhibitors
Zeise's salt derivatives of the potassium trichlorido[η -((prop-2-en/but-3-en)-1-yl)-2-acetoxybenzoate]platinate(II) type (ASA-Prop-PtCl /ASA-But-PtCl derivatives) were synthesized and characterized regarding their structure, stability, and biological activity. It is proposed that the leads ASA...
Gespeichert in:
Veröffentlicht in: | Pharmaceutics 2023-05, Vol.15 (6), p.1573 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Zeise's salt derivatives of the potassium trichlorido[η
-((prop-2-en/but-3-en)-1-yl)-2-acetoxybenzoate]platinate(II) type (ASA-Prop-PtCl
/ASA-But-PtCl
derivatives) were synthesized and characterized regarding their structure, stability, and biological activity. It is proposed that the leads ASA-Prop-PtCl
and ASA-But-PtCl
interfere with the arachidonic acid cascade as part of their mode of action to reduce the growth of COX-1/2-expressing tumor cells. With the aim to increase the antiproliferative activity by strengthening the inhibitory potency against COX-2, F, Cl, or CH
substituents were introduced into the acetylsalicylic acid (ASA) moiety. Each structural modification improved COX-2 inhibition. Especially compounds with F substituents at ASA-But-PtCl
reached the maximum achievable inhibition of about 70% already at 1 µM. The PGE
formation in COX-1/2-positive HT-29 cells was suppressed by all F/Cl/CH
derivatives, indicating COX inhibitory potency in cellular systems. The CH
-bearing complexes showed the highest cytotoxicity in COX-1/2-positive HT-29 cells with IC
values of 16-27 µM. In COX-negative MCF-7 cells, they were 2-3-fold less active. These data clearly demonstrate that it is possible to increase the cytotoxicity of ASA-Prop-PtCl
and ASA-But-PtCl
derivatives by enhancing COX-2 inhibition. |
---|---|
ISSN: | 1999-4923 1999-4923 |
DOI: | 10.3390/pharmaceutics15061573 |